Vir Biotechnology, Inc. Stock-Based Compensation
Vir Biotechnology, Inc. (VIR) reported Stock-Based Compensation of $24.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $12.39M, a 0.48% decline year-over-year.
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $12.09M, a 14.03% decline year-over-year.
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $11.21M, a 29.26% decline year-over-year.
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $11.36M, a 31.99% decline year-over-year.
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $49.07M, a 37.45% decline from fiscal 2024.
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $78.46M, a 29.52% decline from fiscal 2023.
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $111.32M, a 9.05% increase from fiscal 2022.
- Vir Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $102.08M, a 21.84% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $24.48M 10-Q · filed 2026-08-05 | $35.68M derived: sum of 3 quarters · filed 2026-08-05 | $47.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $12.09M 10-Q · filed 2026-05-07 | $23.29M derived: sum of 2 quarters · filed 2026-05-07 | $34.65M derived: sum of 3 quarters · filed 2026-05-07 | $47.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $22.56M derived: sum of 2 quarters · filed 2026-02-23 | $35.01M derived: sum of 3 quarters · filed 2026-08-05 | $49.07M 10-K · filed 2026-02-23 |
| 2025-09-30 | $11.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $23.81M derived: sum of 2 quarters · filed 2026-08-05 | $37.87M 10-Q · filed 2025-11-05 | $53.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $12.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $26.51M 10-Q · filed 2026-08-05 | $42.35M derived: sum of 3 quarters · filed 2026-08-05 | $59.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $14.06M 10-Q · filed 2026-05-07 | $29.90M derived: sum of 2 quarters · filed 2026-05-07 | $46.60M derived: sum of 3 quarters · filed 2026-05-07 | $68.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $32.54M derived: sum of 2 quarters · filed 2026-02-23 | $54.70M derived: sum of 3 quarters · filed 2026-02-23 | $78.46M 10-K · filed 2026-02-23 |
| 2024-09-30 | $16.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $38.86M derived: sum of 2 quarters · filed 2025-11-05 | $62.62M 10-Q · filed 2025-11-05 | $90.89M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $22.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $45.92M 10-Q · filed 2025-08-06 | $74.19M derived: sum of 3 quarters · filed 2026-02-23 | $101.14M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $23.76M 10-Q · filed 2025-05-08 | $52.03M derived: sum of 2 quarters · filed 2026-02-23 | $78.97M derived: sum of 3 quarters · filed 2026-02-23 | $109.59M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $28.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $55.22M derived: sum of 2 quarters · filed 2026-02-23 | $85.83M derived: sum of 3 quarters · filed 2026-02-23 | $111.32M 10-K · filed 2026-02-23 |
| 2023-09-30 | $26.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $57.56M derived: sum of 2 quarters · filed 2024-11-04 | $83.04M 10-Q · filed 2024-11-04 | $107.91M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $30.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $56.10M 10-Q · filed 2024-08-01 | $80.97M derived: sum of 3 quarters · filed 2025-02-27 | $105.78M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $25.48M 10-Q · filed 2024-05-03 | $50.35M derived: sum of 2 quarters · filed 2025-02-27 | $75.16M derived: sum of 3 quarters · filed 2025-02-27 | $102.26M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $24.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $49.68M derived: sum of 2 quarters · filed 2025-02-27 | $76.78M derived: sum of 3 quarters · filed 2025-02-27 | $102.08M 10-K · filed 2025-02-27 |
| 2022-09-30 | $24.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $51.91M derived: sum of 2 quarters · filed 2023-11-03 | $77.22M 10-Q · filed 2023-11-03 | $101.59M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $27.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $52.40M 10-Q · filed 2023-08-04 | $76.77M derived: sum of 3 quarters · filed 2024-02-26 | $99.72M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $25.30M 10-Q · filed 2023-05-08 | $49.67M derived: sum of 2 quarters · filed 2024-02-26 | $72.62M derived: sum of 3 quarters · filed 2024-02-26 | $93.62M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $24.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $47.31M derived: sum of 2 quarters · filed 2024-02-26 | $68.31M derived: sum of 3 quarters · filed 2024-02-26 | $83.78M 10-K · filed 2024-02-26 |
| 2021-09-30 | $22.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $43.94M derived: sum of 2 quarters · filed 2022-11-03 | $59.41M 10-Q · filed 2022-11-03 | $69.71M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $36.47M 10-Q · filed 2022-08-09 | $46.77M derived: sum of 3 quarters · filed 2023-02-28 | $55.35M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $15.47M 10-Q · filed 2022-05-05 | $25.77M derived: sum of 2 quarters · filed 2023-02-28 | $34.35M derived: sum of 3 quarters · filed 2023-02-28 | $40.10M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $18.88M derived: sum of 2 quarters · filed 2023-02-28 | $24.63M derived: sum of 3 quarters · filed 2023-02-28 | $27.60M 10-K · filed 2023-02-28 |
| 2020-09-30 | $8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $14.33M derived: sum of 2 quarters · filed 2021-11-04 | $17.30M 10-Q · filed 2021-11-04 | $19.98M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $8.72M 10-Q · filed 2021-08-05 | $11.40M derived: sum of 3 quarters · filed 2022-02-28 | $13.58M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.97M 10-Q · filed 2021-05-06 | $5.65M derived: sum of 2 quarters · filed 2022-02-28 | $7.83M derived: sum of 3 quarters · filed 2022-02-28 | $9.23M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.87M derived: sum of 2 quarters · filed 2022-02-28 | $6.27M derived: sum of 3 quarters · filed 2022-02-28 | $8.72M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $3.59M derived: sum of 2 quarters · filed 2020-11-10 | $6.04M 10-Q · filed 2020-11-10 | $6.99M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $3.85M 10-Q · filed 2020-08-11 | $4.80M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $2.45M 10-Q · filed 2020-05-12 | $3.40M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $952.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.05M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $4.10M 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $4.78M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |